- Special Sections
- Public Notices
The Department of Energy’s National Nuclear Security Administration announced this week the award of a cooperative agreement that accelerates the dual objectives of eliminating the use of proliferation-sensitive highly enriched uranium (HEU) in the production of medical isotopes and establishing reliable domestic supplies of Molybdenum-99 (Mo-99) to meet U.S. patient needs.
Mo-99 is used frequently in common medical diagnostic procedures. The cooperative agreement with NorthStar Medical Radioisotopes, LLC provides support toward NorthStar’s Mo-99 production capability using neutron-capture technology, which it is pursuing in partnership with the University of Missouri Research Reactor.
“This cooperative agreement demonstrates that the government and commercial industry can work together to reduce the risk of nuclear proliferation while providing stability to an important part of the medical radioisotope market,” said NNSA Deputy Administrator for Defense Nuclear Nonproliferation Anne Harrington.
“The development of commercial technologies to produce Mo-99 without the use of HEU will ensure that patients have access to the care they need while supporting global nuclear nonproliferation objectives.”